in vivo and to establish that TCF21 and its regulation of SMC phenotype in atherosclerosis are causally protective for CHD.
What of the authors' broader inference that SMC phenotype modulation is atheroprotective? If true, this concept could accelerate the development of therapeutics because it would alleviate previous concerns that targeting SMCs might have both pro-and anti-atherogenic effects. This broader conclusion is based on the authors' single-cell profiling, which suggests that SMCs transition almost exclusively to fibromyocytes, but not at all to macrophagelike cells, during 16 weeks of disease progression in the ApoE -/-mouse model. Indeed, Wirka et al. find that trajectories of gene expression in SMC-derived cells move further away from lesion macrophages during diseases progression. This is an unexpected result, as multiple recent studies have reported identifying SMC-derived macrophage-like cells using SMC fatemapping strategies, flow cytometry and immunohistochemistry [6] [7] [8] . In those studies, SMC-derived macrophages have been reported to constitute a sizeable proportion of all SMC-derived lesion cells in both advanced mouse and human atherosclerosis. Such inference, however, was based largely on single cell-surface protein markers. The current analyses combining scRNA-seq with simultaneous profiling of multiple cell surface markers reveal that previously proposed cell-specific protein markers (e.g., Lgals3) are expressed on multiple cell types in mouse and human disease.
However, the concept that SMC phenotype modulation is dependably atheroprotective needs further investigation. First, it should be noted that Wirka et States and 1% of the global population over 60 years of age 1 . A hallmark of PD is the loss of dopamine-producing neurons in the striatum, which results in debilitating motor problems. Over the last 50 years, the mainstay treatment for motor symptoms in PD has been the drug levodopa (l-dopa). l-dopa crosses the blood-brain barrier and is metabolized in the brain by the enzyme aromatic amino acid decarboxylase (AADC) to produce dopamine, the active therapeutic agent. Despite its widespread use, there are many adverse side effects associated with l-dopa treatment, and its efficacy varies highly across patients. This is largely due to AADC's ability to decarboxylate l-dopa to dopamine in peripheral organs such as the small intestine and liver before it can enter the brain 2 . As such, l-dopa is often prescribed along with enzyme inhibitors such as carbidopa in attempt to minimize its peripheral metabolism. Given that l-dopa is commonly administered orally or enterally, scientists have proposed that the gut microbiome may also influence treatment efficacy [3] [4] [5] . Indeed, individual bacterial species are known to express enzymes involved in catechol metabolism 6 , but whether indigenous bacteria from the gut microbiome actually influence l-dopa metabolism has been unclear. In a recent study in Science, Redkal and colleagues identify a previously unidentified pathway for bacterial l-dopa metabolism that can be inhibited to promote l-dopa bioavailability.
The authors first mined genomic databases to identify candidate bacterial species that contain sequences similar to those of tyrosine decarboxylases (tyrDCs) previously shown to have promiscuous activity toward l-dopa 6 . They then tested these candidates for their activity in culture and found that only one species, Enterococcous faecalis, completely metabolized l-dopa. When they generated mutations that rendered the tyrDC enzyme inactive, the bacteria were no longer able to decarboxylate l-dopa to dopamine. This demonstrated that bacterial tyrDCs can metabolize l-dopa and suggested that the gut microbiome could reduce the peripheral availability of the drug.
The authors next examined the conversion of dopamine to m-tyramine by dehydroxylation, because this activity is thought to contribute to the adverse side effects associated with peripheral l-dopa metabolism 7 . As dehydroxylation of dopamine had not previously been reported for any bacterial isolate, they turned to enrichment culturing, whereby bacteria are grown in selective media that favor the growth of particular microorganisms over others. By adding dopamine to cultures, the authors identified a single bacterium, called Eggerthella lenta, that was enriched in the culture and that converted dopamine to m-tyramine. To identify the dopamine-dehydroxylating enzyme (Dadh) in E. lenta, the authors profiled the genes whose expression increased in response to dopamine. Three genes were upregulated, which together encode a bis-molybdopterin guanine dinucleotide cofactor (moco)-containing enzyme. Based on this, the authors identified 26 additional bacterial species harboring these genes and screened them for dehydroxylation activity in culture. Of the 26 species, only 10 were capable of converting dopamine to m-tyramine, even though all of them harbored dadh genes. Overall, this study was the first to identify bacteria that dehydroxylate dopamine.
To better understand what might differentiate these dopamine metabolizers from non-metabolizers, the authors profiled the gene expression of bacteria from each category. Surprisingly, dadh was upregulated in the presence of dopamine in all species tested, suggesting that differences in metabolic activity did not arise from differences in transcription. Instead, they found that a single-nucleotide difference in the dadh genes almost perfectly predicted metabolizer status.
Having identified two bacterial enzymes capable of carrying out sequential steps in l-dopa metabolism, the authors next asked whether E. faecalis and E. lenta could together convert l-dopa to m-tyramine. Indeed, when the two species were co-cultured, l-dopa was completely converted to m-tyramine in a tyrDC-dependent manner. Attempting to gain insight into whether similar microbial interactions may occur in humans, the authors found that the levels of E. faecalis and tyrDC in human microbiota samples correlated with differences in l-dopa metabolism. When they added E. faecalis to cultures of bacteria from non-metabolizers, l-dopa was fully depleted. To assess the clinical relevance of these findings, they obtained fecal samples from patients with PD who had varying levels of l-dopa metabolism. They found that, indeed, the abundance of E. faecalis and tyrDC again correlated with metabolic status in the patient samples. Together these data raise the prospect that levels of E. faecalis and tyrDC in the gut microbiome could serve as biomarkers for the efficacy of l-dopa treatment in patients with PD. The authors' findings also suggest that drugs that inhibit microbial enzymes involved in l-dopa metabolism could increase the amount of l-dopa available to enter the brain. To determine whether the identified bacterial pathways could be inhibited with small molecules, the authors tested (S)-α-fluoromethyltyrosine (AFMT) as a potential decarboxylase inhibitor, based on their findings from a survey of potential substrates. When they added AFMT to human microbiota samples in culture, l-dopa levels were maintained at higher levels. To test whether a similar effect would occur in animals, the authors inoculated germ-free mice with E. faecalis and treated them with l-dopa plus AFMT or a vehicle control. AFMT significantly increased the peak circulating concentrations of l-dopa, suggesting that it effectively inhibited metabolism of l-dopa by E. faecalis. These findings warrant continued study into whether AFMT could increase the efficiency of l-dopa in patients with PD who exhibit high peripheral l-dopa metabolism. Overall, the study adds to the growing body of work describing microbial effects on drug metabolism 8, 9 and underscores the importance of examining the role of microbial metabolic activity during drug treatment to reduce interpatient variability and enhance drug efficacy. Importantly, the study uncovers fundamental pathways for bacterial metabolism of l-dopa that could inform novel approaches for treating PD (Fig. 1) 
